Please find the enclosed intimation of the Company as per the captioned subject for your reference.

November 07, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai - 400001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra –Kurla Complex, Bandra (E), Mumbai - 400051 Dear Sir/ Madam, Subject: Launch of Datopotamab Deruxtecan (Brand name: Datverzo) We refer to our earlier communication dated 17th December, 2025 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Datopotamab Deruxtecan (Brand name: Datverzo). With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited will launch Datverzo in India in November 2026. Datverzo is already approved for treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease iu adults with HR+/HER2– mBC. We request you to take the above intimation on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No.: A25784